Search

everythinglearnresearchcommunity

for

Search:↓

Combining minoxidil 5%, tazarotene 0.1% cream, and lumigan for hair loss treatment is discussed. The conversation focuses on the safety and effectiveness of using these treatments together.

A user shared their 2-year results using only 0.5mg finasteride for hair loss, noting improvement after 8-10 months and no major shedding or side effects. They are 34 years old and have avoided using Minoxidil.

User reports 2 months of hair growth using Minoxidil 5% twice daily and 0.5 Finasteride once daily. Different Minoxidil brand and increased application frequency may have contributed to success.

Oral minoxidil has greatly improved eyelash growth, prompting compliments and questions about mascara use. The user has been taking 2.5mg of oral minoxidil for three months and is also using finasteride.

The user started oral finasteride and minoxidil in November 2024, initially saw improvement, but has experienced increased shedding since April 2025. They are concerned the treatment may not be effective anymore and seek advice.

The user has been using topical finasteride and minoxidil for a month to address hair thinning. They are experiencing shedding but have noticed small hairs on their temples.

A user shared their 2.5-year hair loss treatment success using 1mg finasteride daily and switching from 5mg to 2.5mg minoxidil. They reported no significant side effects and emphasized the importance of early treatment.

Regenera Activa and exosome therapy are discussed for hair loss treatment, focusing on their effectiveness for regrowth, thickening, or reducing shedding. Users are seeking experiences and results from these treatments.

A user shared their 9-month progress using oral 1 mg finasteride and oral 5 mg minoxidil for hair loss, reporting significant improvement and no lasting side effects. Other users praised the results and inquired about the treatment details.

The conversation discusses hair loss treatments, specifically the use of finasteride (Fin) and oral minoxidil (Oral Min), with progress shown using hair fibers like DermMatch and Toppik. The original poster plans a hair transplant and mentions side effects like reduced libido from finasteride.

The conversation is about hair loss treatments, specifically asking for updates on verteporfin research following promising results. No specific treatments were discussed in the provided text.

A 23-year-old male experienced no shedding with RU58841 but switched to oral finasteride due to heart concerns, resulting in increased hair shedding. He is considering adding minoxidil to his regimen, which currently includes finasteride, Nizoral shampoo, and microneedling.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

The user experienced hair regrowth after 5 months using 1 mg oral finasteride, topical minoxidil almost daily, and Nizoral weekly. They noticed improvements in hair volume and color, attributing changes to lighting rather than hair dye.

This conversation is about a user's progress pictures after using minoxidil twice a day and microneedling for 1.5 months, with other users recommending finasteride as an additional treatment. They are also discussing the frequency and depth of the microneedling.

A 56-year-old user shared progress pictures from January to June 2024, detailing their hair loss treatment journey. They used Nanoxidil, oral Minoxidil, Finasteride (later switched to Dutasteride), RU58841, and LLLT therapy, noting slow but visible improvements.

RU58841's potential toxicity to cats is uncertain, similar to minoxidil. Caution is advised to prevent accidental exposure to pets.

The user has been using finasteride, minoxidil, retinoid, and occasional microneedling for hair loss with good results. They recently added stemoxydine, which improved their hair further, and suggest trying it, especially in the EU where it's easily available.

Finasteride has shown great results for hair loss. The discussion also inquires about the effectiveness and side effects of Low-Level Laser/Light Therapy (LLLT).

The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.

Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.

The user is experiencing prolonged hair shedding despite using 1mg finasteride, 2.5mg minoxidil, and considering adding topical finasteride. They are also deficient in Vitamin D and B, and are exploring if supplements or dosage adjustments could help.

New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

User reported initial hair regrowth with 0.25 mg finasteride taken four times a week, experiencing a second shedding phase, and no side effects. They also mentioned using RU58841 without success and plan to stop after a year.

The user reported significant hair regrowth using a topical treatment of 0.3% finasteride and 6% minoxidil, with noticeable progress in five months. The treatment is applied once daily, and the user experienced some initial shedding but no side effects.

The user has been using topical minoxidil, finasteride, microneedling, and laser light therapy for 11 weeks to address hair thinning. They report difficulty applying the treatment due to increased hair thickness and are unsure if the results are significant.